Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 7
Balancing Clinical and Patient-Centered Factors in 1L EGFRm NSCLC Treatment
Panelists discuss how patient-centered factors are crucial in shared decision-making for first-line (1L) treatment, with a potential default approach of offering combination therapy with an option to choose osimertinib monotherapy.
Patient-Centered Factors in Treatment Decision-Making
Main Discussion Topics:
- Incorporating patient goals and preferences into treatment selection
- Approaches to shared decision-making in time-limited clinical visits
- Use of risk stratification strategies to guide treatment intensity
Key Points for Physicians:
- With significant survival data, combination therapy may become the default with an “opt-out” approach
- Liquid biopsy (circulating tumor DNA clearance) can help stratify patients who might benefit from treatment escalation
- All treatments (chemotherapy, amivantamab, EGFR inhibitors) will likely be used at some point in the disease course
Notable Insights:
Treatment sequencing must consider that not all patients receive 2L therapy, making it critical to optimize 1L treatment selection.
Clinical Significance:
A nuanced approach to 1L therapy involves balancing evidence-based recommendations with individualized assessment of risk and patient preferences.
Related Content:
